Thulo Molefi
Background: Immunotherapy and molecularly targeted therapy have revolutionised the treatment of malignant melanoma, however for South Africa’s public health sector patient population, these treatment modalities are far out of reach and chemotherapy remains the only treatment option.
Aim: To evaluate the outcomes of advanced melanoma and determine the need for therapies other than conventional chemotherapy in South Africa’s public health sector.
Setting: The Department of Medical Oncology, Steve Biko Academic hospital (SBAH), Pretoria, South Africa.
Methods: Files of patients with advanced malignant melanoma managed at SBAH, from 01 January 2009 to 31 December 2019 were retrospectively reviewed.
Results: One hundred files meeting the inclusion criteria were analysed, 24 with regional (stage III) and 76 with metastatic (stage IV) disease. 23 (96%) patients with regional disease didn’t receive adjuvant therapy and had a median time to progression (MTTP) of 12 months (95%CI; 8.9-15.0). Within the metastatic melanoma cohort, 34 (79.1%) patients received chemotherapy and had a median overall survival (MOS) of 5 months (95% CI; 4.3-5.6), while patients that didn’t receive chemotherapy had a MOS of 2 months (95% CI; 0.8-3.1) (p=0.213).
Conclusion: These results reaffirm the impotent effects of chemotherapy in treating malignant melanoma and it is imperative that South Africa’s public health sector expands its armamentarium against this lethal disease.
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi